Category Archives: Molecular Genetics

NEW YORK--(BUSINESS WIRE)--IVERIC bio, Inc. (NASDAQ: ISEE) announced today the appointment of Guangping Gao, PhD, as Chief Strategist, Gene Therapy. Dr. Gao brings over 30 years of scientific research experience in gene-based treatments. As one of the worlds leading gene therapy experts, Dr. Gaos highly distinguished career includes major contributions to the development of adeno-associated virus (AAV) gene delivery technology. Dr. Gao is the current President of the American Society of Gene and Cell Therapy (ASGCT). In his advisory role, Dr. Gao will help shape IVERIC bios gene therapy strategy going forward.

On behalf of the Board of Directors and management team at IVERIC bio, we are extremely excited to welcome Dr. Gao to IVERIC bio, stated Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio. Our goal at IVERIC bio is to become a leading retina company with a diversified portfolio addressing significant unmet medical needs in large market age-related retinal indications and inherited retinal diseases by utilizing both therapeutics and gene therapies. Dr. Gaos extensive background in gene therapy will be instrumental in shaping the direction of our gene therapy portfolio. It is a true privilege to work with him closely and benefit from his extensive expertise during these exciting times at our company.

I am delighted to have the opportunity to be a part of the IVERIC bio team, stated Dr. Gao. I am impressed with the progress that IVERIC bio had made with their diverse pipeline of novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs). I look forward to working closely with the team to help build and maximize the potential of the Companys gene therapy programs.

Dr. Gao is a world-renowned scientist and researcher who is a pioneer in AAV gene delivery technology, stated Kourous A. Rezaei, MD, Chief Medical Officer of IVERIC bio. We believe that the combination of Dr. Gaos expertise in gene therapy and our knowledge and experience in drug development for retinal diseases will help set the stage for the proficient execution of our gene therapy strategy, advancing it to the next stage of evolution. We will also continue to move forward our Zimura, complement C5 inhibitor, programs as expeditiously as possible.

About Guangping Gao, PhD

Dr. Gao is the Co-Director, Li Weibo Institute for Rare Diseases Research, Director, Horae Gene Therapy Center and Viral Vector Core, Professor of Microbiology and Physiological Systems and Penelope Booth Rockwell Professor in Biomedical Research, at the University of Massachusetts Medical School; an elected fellow of both the US National Academy of Inventors (NAI) and the American Academy of Microbiology; and the current President of the American Society of Gene and Cell Therapy.

Dr. Gao is an internationally recognized gene therapy researcher who has played a key role in the discovery and characterization of a new family of adeno-associated virus (AAV) serotypes, which was instrumental in reviving the gene therapy field, providing technology to enable potential treatments for many currently untreatable human diseases. For nearly 30 years of his scientific research career, Dr. Gao has primarily focused on molecular genetics and viral vector gene therapy for rare genetic diseases, with research encompassing disease gene cloning, causative mutation identification, pathomechanism investigation, animal modeling, novel viral vector discovery and engineering for in vivo gene delivery, vector biology, preclinical and clinical gene therapy product development, and viral vector manufacturing for preclinical and clinical gene therapy applications, as well as development of technology platforms for novel approaches for human gene therapy.

Dr. Gao has published 267 research papers, 6 book chapters, and 5 edited books and serves as Editor of Human Gene Therapy, Senior Editor of the Gene and Cell Therapy book series, Associate Editor of Signal Transduction and Targeted Therapy, and on the editorial boards of several other gene therapy and virology journals. Dr. Gao holds 135 patents with 239 additional patent applications pending. Dr. Gaos inventions have been licensed to and are currently in development by over ten pharmaceutical companies. Recently, Dr. Gao was ranked as #4 on Nature Biotechnologys list of the Worlds Top 20 Translational Researchers for 2017.

About IVERIC bio

IVERIC bio is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. Vision is Our Mission. For more information on the Company please visit http://www.ivericbio.com.

IVERIC bio Forward-looking Statements

Any statements in this press release about the Companys future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Companys strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words anticipate, believe, estimate, expect, intend, goal, may, might, plan, predict, project, target, potential, will, would, could, should, continue, and similar expressions. In this press release, the Companys forward looking statements include statements about the implementation of its strategic plan to seek to address significant unmet medical needs in large market age-related retinal indications and inherited retinal diseases by utilizing both therapeutics and gene therapies, the timing, progress and results of clinical trials and other research and development activities, including manufacturing activities, the potential utility of its product candidates and the potential for its business development strategy. Such forward-looking statements involve substantial risks and uncertainties that could cause the Companys development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to the initiation and the conduct and design of research programs and clinical trials, establishment of manufacturing capabilities, availability of data from these programs, reliance on university collaborators and other third parties, expectations for regulatory matters, need for additional financing and negotiation and consummation of business development transactions and other factors discussed in the Risk Factors section contained in the quarterly and annual reports that the Company files with the Securities and Exchange Commission. Any forward-looking statements represent the Companys views only as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.

ISEE-G

See the original post here:
IVERIC bio Appoints Guangping Gao, PhD, Internationally Recognized Gene Therapy Pioneer as Chief Strategist, Gene Therapy - Business Wire

It is important to understand that the Molecular Therapy family of journals offers unprecedented opportunities to publish high-quality articles in gene and cell therapy, Herzog says.

MILWAUKEE (PRWEB) November 25, 2019

The American Society of Gene & Cell Therapy (ASGCT) announced today the appointment of Roland W. Herzog, Ph.D. and Gerhard Bauer as editors-in-chief of the Societys field-leading journals, Molecular Therapy and Molecular TherapyMethods & Clinical Development, respectively. Both editors will begin their positions effective January 1, 2020.

Herzog, currently the editor-in-chief of Molecular TherapyMethods & Clinical Development, will assume the same role for a five-year term at Molecular Therapy from Seppo Yl-Herttuala, M.D., Ph.D. at the conclusion of Yl-Herttualas term. Herzog is also a professor of pediatrics, Riley Children's Foundation Professor of Immunology, and director of the gene and cell therapy program at Indiana University.

It is important to understand that the Molecular Therapy family of journals offers unprecedented opportunities to publish high-quality articles in gene and cell therapy, Herzog says. My vision has continued and even further strengthened close coordination and collaboration between the journal editors and partnership with Cell Press and ASGCT.

Bauer replaces Herzog at the helm of Molecular TherapyMethods & Clinical Development after serving as an associate editor of the same journal for more than four years. Bauer is an assistant professor of hematology and oncology and director of the Good Manufacturing Practice (GMP) laboratory at the UC Davis Institute for Regenerative Cures.

Over the years that I have been looking at manuscripts submitted to the journal, I have always loved the articles dealing with translational research, getting the products ready for clinical applications, improving their utility and solving problems in the manufacturing of these products, Bauer says. Now, at a time where we have clinical efficacy and also commercially approved cell and gene therapy products that save lives, it is even more important to strengthen the translational research field.

ASGCTs official journal, Molecular Therapy is the leading journal for research in the areas of gene transfer, vector development and design, stem cell manipulation, development of gene-, peptide-, protein-, oligonucleotide-, and cell-based therapeutics to correct genetic and acquired diseases, vaccine development, pre-clinical target validation, safety/efficacy studies, and clinical trials. Molecular Therapy is dedicated to promoting the sciences in genetics, medicine, and biotechnology. Publishing important peer-reviewed research and cutting-edge reviews and commentaries, the journal continues to attract the best material in the field. Molecular Therapy's 2018 impact factor is 8.402.

The aim of Molecular TherapyMethods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Molecular TherapyMethods & Clinical Development's 2018 impact factor is 4.875.

In addition to Molecular Therapy and Molecular Therapy Methods & Clinical Development, ASGCT also owns and operates two other sibling journals, Molecular TherapyNucleic Acids (2018 impact factor 5.919) and Molecular TherapyOncolytics (2018 impact factor 5.710).

About ASGCTThe American Society of Gene & Cell Therapy is the primary professional membership organization for scientists, physicians, patient advocates, and other professionals with interest in gene and cell therapy. Our members work in a wide range of settings including universities, hospitals, government agencies, foundations, biotechnology and pharmaceutical companies. ASGCT advances knowledge, awareness, and education leading to the discovery and clinical application of gene and cell therapies to alleviate human disease to benefit patients and society.

Share article on social media or email:

Go here to see the original:
Molecular Therapy Family of Journals Welcomes Roland W. Herzog and Gerhard Bauer as Editors-in-Chief - PR Web

One wanted to be a professional basketball player. Another wanted to be a dancer. And someone else wanted to be an astronaut. They all ended up making impacts in different careers.

For our series on Visionaries, The Times interviewed 12 people who are taking risks and working to change the world.

Technology visionary: Jeri Ellsworth

Ms. Ellsworth began playing pinball when she worked in a bowling alley as a teenager, and a manager there would occasionally give her a few free credits. Today, she has a collection of more than 70 pinball machines, but her passion has moved from the mechanical into a new digital augmented reality, which she believes will be the future of entertainment.

Ms. Ellsworth, 45, is a self-taught computer hacker and chip designer who recently started a new augmented reality gaming company, Tilt Five, based in San Jose, Calif. She is emblematic of a generation of Silicon Valley hobbyists who were passionate about computers and only later turned their passions into commercial enterprises. She originally gained visibility as an independent computer chip designer living in a rural ramshackle farmhouse in Yamhill, Ore. Read more

FOOD VISIONARY: Steve Palmer

Mr. Palmer has opened dozens of restaurants over the course of his career. He knows how to coax the best flavors out of a piece of fish, how to light a restaurant so all the customers look good and how to make a couple celebrating an anniversary feel special.

But 18 years ago, he was so strung out on alcohol and cocaine that his boss at the restaurant where he worked gave him an ultimatum: Get treatment or get fired.

He chose rehab. Now, Mr. Palmer, 50, is the managing partner of Indigo Road Hospitality Group, which employs about a thousand people in 20 restaurants and bars that stretch across four Southern states and Washington. Read more

Style visionary: Iris van Herpen

When many people think of couture they think of the most traditional, time-intensive kind of fashion; of seamstresses and tailors in white coats bent over intricate swathes of material painstakingly sewing by hand the way they have since the days of Charles Frederick Worth and Christian Dior (and Marie Antoinette, for that matter).

Ms. van Herpen, however, a 35-year-old Dutch designer who founded her own company in 2007, has always thought of something different.

She has thought of the way the sewing needle an early tool might translate into the tools of tomorrow; might, for example, connect to the 3-D printer and the laser cutter. She has explored such themes as biopiracy and magnetic motion; has combined mylar and copper with tulle and organza. Her dresses often appear to have their own energy field and look as though they are terraforming the body. Read more

Education Visionary: Jeff Duncan-Andrade

Sometimes it is the child who hates school who cares most about fixing its failings.

Which is how you can think of Mr. Duncan-Andrade. The youngest of seven who was born in Los Angeles and whose family moved from to Sacramento to Oregon to Oakland, Calif., during his school years found his teachers uninspiring. He only went to school to play ball.

But sports, specifically travel basketball, opened his eyes to the gulf between toxic coaches and those who forged relationships. Today, as an education activist, teacher, education coach, San Francisco State University associate professor and scholar, he is driving a public conversation that upends traditional beliefs about reforming schools and achieving equity. Read more

Culture Visionary: Shirin Neshat

Ms. Neshat has had an unusual trajectory to art world prominence. The artist left her native Iran as a teenager in the 1970s, before the revolution and the fall of the shah, and ended up studying at the University of California, Berkeley. By her own account, she didnt end up making art seriously until her early 30s. But Ms. Neshat, 62, has become one of the most distinct practitioners in the media of photography, video and film.

Now New York-based and working with several assistants in a large Bushwick studio, Ms. Neshat makes art that touches on topics like exile, political revolution and Irans past and future. The biggest exhibition of her career, Shirin Neshat: I Will Greet the Sun Again, runs from Oct. 19 to Feb. 16 at The Broad in Los Angeles. Read more

science visionary: Edith Heard

Twice in her life, Professor Heard has transformed scientific understanding.

She studies epigenetics changes to genetic activity that can be passed down to daughter cells without affecting the underlying genetic code. Among bees, for example, a simple difference in food supply means that a larva becomes either a worker or a queen.

Professor Heards first major advance was showing that these kinds of epigenetic changes can be incredibly dynamic, particularly as an embryo forms and matures. In her second, she revealed important information about how parts of the genome fold in space, allowing some genes to be activated and others silenced.

In January, Professor Heard took over as head of the European Molecular Biology Laboratory, or E.M.B.L., a scientific collaboration among 27 European countries. She received her bachelors degree in genetics from Cambridge Universitys Emmanuel College and her doctorate in biochemistry from the Imperial Cancer Research Fund in London. She is also a professor at the Collge de France. Read more

architecture visionary: Vo Trong Nghia

As city dwellers seek to soften the expanding urban jungle around them, architects are working harder to incorporate greenery and natural materials. But nobody is doing it quite like Mr. Nghia.

His firm, Vo Trong Nghia Architects, based in Ho Chi Minh City, infuses its work with lushly planted walls, hanging vines, structure-piercing trees, weathered stones and sunken landscapes. It also incorporates traditional Vietnamese building techniques, like complex bamboo trusses, perforated blocks, cooling water systems, shaded terraces and thatched roofs. Mr. Nghias firm also is expanding into prefab housing, urban farms, green towers, parks and urban plans around Asia.

All these efforts are infused with a resolute vision: the creation of architecture that merges nature, local vernacular and through modern materials and methods contemporary design. Mr. Nghia sees such work as a way not only to refine the urban environment, but also to provide a sense of peace in the world. Read more

agriculture visionary: Thomas Njeru

Few livelihoods offer as many paths to failure as agriculture. Throughout history, farmers have been at the mercy of nature be it weather, pests or crop diseases even as the survival of people and livestock depended on their success.

Growing up on a farm on the slopes of Mount Kenya, Mr. Njeru witnessed firsthand the devastating impact such setbacks had on the lives of small landholders, including his own family. His mother lectured him to work hard in school so he could one day leave the farm and land a good job in the city. Mr. Njeru followed that advice obediently until he did not.

Today, he is a co-founder and the chief financial officer of Pula, a four-year-old microinsurance firm that serves 1.7 million smallholder farms of 0.6 acres or less in 10 African countries and India. Read more

infrastructure visionary: james ehrlich

For Mr. Ehrlich, farm-to-table is just a starting point for the future.

The New York native, who migrated to Silicon Valley decades ago, is the founder and president of ReGen Villages, which seeks to create self-reliant ecosystems globally.

Mr. Ehrlich is anything but a typical real estate developer. Instead, his company, which he started in 2016, derives from his concern for the environment and his love of farming communities. His idea is to establish a far-reaching plan to create new neighborhoods that will generate their own power through solar photovoltaic panels, biomass and biogas from material, food and animal waste, and geothermal sources, to name but a few. Read more

sports visionary: Rich Luker

The sports world is filled with people whose job is to sell tickets, advertisements, sponsorships, luxury boxes and all manner of game-day experiences. The more, the better. Any fan will do.

Dr. Luker has tried to get those managers, supervisors and executives to look for something more profound, something he calls lifetime value.

To Dr. Luker, the most concrete iteration of that concept is the idea that passionate fans would get a tattoo of their favorite teams logo to show that it is part of their core identity.

This is just one of the discoveries he has made over the past 25 years as the founder of Luker On Trends, a sports polling company that works with many professional sports leagues and teams. Read more

BUSINESS VISIONARY: Andrew Kassoy

Sometimes its better not to know the obstacles that exist when creating something new.

That was certainly true for Mr. Kassoy, who, along with Jay Coen Gilbert and Bart Houlahan, two friends and roommates from Stanford University, wanted to encourage companies to focus on their employees and the environment. In 2006, they left their jobs and created B Lab, which certifies companies that operate for social good, in addition to trying to make money. Think Fair Trade for food or LEED certification for environmentally sustainable buildings.

Certified companies referred to as B Corps are businesses with verified social and environmental performances, including factors such as sustainability, income inequality and the impact on local communities. They are, essentially, companies that use business as a force of good, rather than focusing solely on profit maximization. Read more

Climate Visionary: Narasimha Rao

When policymakers, financiers and scientists describe the world decades from now, in the throes of climatic changes that we now only model, they emphasize what might be lost. They discuss the threats to gross domestic product, the havoc wrought by natural disasters or the runaway greenhouse gas emissions released by emerging national economies.

To Mr. Rao, a professor at the Yale School of Forestry and Environmental Studies specializing in energy systems analysis, that is a false choice, one that sacrifices justice on the altar of economic growth. Read more

Original post:
A Teacher, an Artist, a Scientist and More. Theyre All Visionaries. - The New York Times

This post was updated Nov. 20 at 7:47 p.m.

A University of California professor and co-originator of genome editing technology Clustered Regularly Interspaced Short Palindromic Repeats said researchers plan to expand the technology in order to increase human applications at a campus lecture series Thursday.

Jennifer Doudna, a UC Berkeley biochemistry professor, engaged students and the greater UCLA science community during the quarterly Donald J. Cram Distinguished Lecture series.

The Cram lecture series, a quarterly departmental event, invites prominent academics in the field of chemistry to speak about their research. The series is dedicated to Donald J. Cram, who was a Nobel laureate and a chemistry professor at UCLA for over 50 years.

This fall, the series was hosted by UCLA chemistry professor and Cram Chair Patrick Harran.

Scientists use CRISPR technology, formally known as CRISPR-Cas9, to modify DNA sequences and gene functions. Cas9 is a protein that can act like molecular scissor to cut the strands of DNA.

CRISPR is studied and used by students, scientists and researchers to advance progress in the field of gene editing, in medicine and the life sciences.

The UC holds the largest CRISPR patent portfolio in the nation with 16 total patents, according to a UC Berkeley press release.

The United States Patent and Trademark Office granted the UC, along with the University of Vienna and Emmanuelle Charpentier, the director of the Max Planck Institute for Infection Biology, its 16th patent in October.

Doudnas involvement in CRISPR technology began around 2005, when a professor at UC Berkeley, Jill Banfield, invited Doudna to help her with research into the mechanism. From there, Doudna teamed up with Charpentier, who was working with a CRISPR system and its associated protein, Cas9, in 2011.

Doudna is one of the creators of the CRISPR utility for the permanent excision of harmful genes. Doudna said that she developed the idea for the CRISPR technology in 2011 in collaboration with Charpentier.

During the lecture, Doudna detailed how scientists regulate CRISPR enzymes to modify DNA.

CRISPR is a portion of the bacterial genomic sequence that acts as an adaptive immune system, Doudna said.

Bacteria encode the CRISPR system through viral infections, which allows its genome to recognize foreign DNA insertions. These DNA sequences incorporate themselves into the bacterial genome at the CRISPR locus, a genetic database of past infections.

Doudna said this locus was of unique interest to her.

Those sequences, called CRISPR, are transcribed in RNA molecules that provide the zip codes for Cas proteins, allowing them to recognize foreign DNA and cut it up, Doudna said.

Doudna and Charpentier, with the assistance of their team, were able to realize that CRISPR RNA is a 20-nucleotide sequence, which interacts with DNA in a complementary fashion.

This complementarity allows the protein to form a double-stranded break in DNA, necessitating a second RNA tracrRNA to form this functional unit, Doudna said.

And it was (biochemist) Martin Jinek in our lab who figured out that you could combine these two RNAs into a single guide RNA, Doudna said.

From this experiment, Jinek found that single guide RNAs were used by Cas9 to excise DNA at specific sites in a plasmid, a circular piece of bacterial DNA. The revelation from this was that, upon excision, DNA would repair itself in animals and plants, Doudna said.

Doudna said at the end of her talk that the system is becoming increasingly important in the field of medicine, and is currently being used at UCLA, by Donald Kohn, a professor of microbiology, immunology and molecular genetics.

Were within about five years, maybe less, from being able to make, essentially, any change to any genome in any type of cell, Doudna said.

Doudna stressed that this ability to make changes in the genome comes with bioethical responsibility for genome editing in humans.

Fourth-year biochemistry student Jeremy Shek, who attended the event, said although he had done a project that was an offshoot of CRISPR, he had not heard of the progress Doudna discussed.

It is important to be informed on advancements and progress in the field, he added.

Fourth-year bioengineering student Timothy Yu said he came to the lecture to see Doudna in person and get a more solid grasp on the methodology of CRISPR.

Lexi Omholt, a fourth-year microbiology, immunology and molecular genetics student, said that she came to the talk to understand the basis of CRISPR technology.

Jennifer Doudna was one of the reasons I chose my major, Omholt said. At that time, CRISPR came into popular knowledge, and the knockout tool was just coming into use. I am involved in a cancer lab, the Soragni Lab, that uses CRISPR-Cas9 on a regular basis.

See original here:
Co-creator of CRISPR lectures about future applications of genome editing technology - Daily Bruin

Salt Lake City, UT (GLOBE NEWSWIRE) -Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced that Japans Ministry of Health, Labour and Welfare (MHLW) has approved the BRACAnalysisDiagnostic System (i.e., BRACAnalysis) to help physicians determine which women with breast cancer have Hereditary Breast and Ovarian Cancer (HBOC) syndrome and qualify for additional medical management. BRACAnalysis is a genetic test that identifies germline mutations in theBRCA1/2genes.

We are excited that the MHLW has approved the BRACAnalysis Diagnostic System for HBOC risk assessment in patients with breast cancer, said Seigo Nakamura, M.D., Ph.D., Professor and Chairman, Department of Surgery, Division of Breast Surgical Oncology and Director, Breast Center of Showa University Hospital in Tokyo and president of the Japanese Organization of Hereditary Breast and Ovarian Cancer (JOHBOC). Our goal is to use the BRACAnalysis test to identify patients withBRCAmutations and determine who will benefit from more advanced medical care.

Under the MHLW decision, physicians may use BRACAnalysis to test forBRCAmutations in women with breast cancer who meet the genetic testing guidelines defined by JOHBOC. Those patients who test positive for a deleteriousBRCAmutation will be eligible to receive advanced medical management, such as prophylactic surgery or targeted therapies.

Myriads BRACAnalysis test is the gold standard forBRCAtesting. The approval of BRACAnalysis for HBOC risk assessment in Japan is further validation of the quality and utility of our pioneering genetic test, said Gary A. King, executive vice president of International Operations, Myriad Genetics. We look forward to working with our commercial partners in Japan to ensure that BRACAnalysis is available to patients.

Myriad has an exclusive partnership with SRL Inc., a subsidiary of Miraca Group, to commercialize the BRACAnalysis Diagnostic System in Japan.

Todays announcement follows two prior regulatory approvals for the BRACAnalysis Diagnostic System in Japan. In February 2019, BRACAnalysis was approved as a companion diagnostic for Lynparza(olaparib) in women with ovarian cancer, and in March 2018, it was approved as a companion diagnostic for Lynparza in patients with metastatic inoperable or recurrent breast cancer.

About the BRACAnalysisDiagnosticSystemBRACAnalysis is a diagnostic system that classifies a patients clinically significant variants (DNA sequence variations) in the germlineBRCA1andBRCA2genes. Variants are classified into one of the five categories; Deleterious, Suspected Deleterious, Variant of Uncertain Significance, Favor Polymorphism, or Polymorphism. Once the classification is completed, the results are sent to medical personnel in Japan for determining the eligibility of patients for treatment with Lynparza.

About SRLSince the establishment in 1970, SRL, Inc., a member of the Miraca Group, Japan-based leading healthcare group, has been providing comprehensive testing services as the largest commercial clinical laboratory in Japan. SRL carries out nearly 400,000,000 tests per year, covering a wide range of testing services including general/emergency testing, esoteric/research testing, companion diagnostics tests, genomic analysis, and etc. For more information, please visithttps://www.srl-group.co.jp/english/.

About Myriad GeneticsMyriad Genetics Inc., is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website:www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Lynparza is a registered trademark of AstraZeneca.

Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Japans Ministry of Health, Labour and Welfare (MHLW) marketing approval of the companys BRACAnalysis Diagnostic System to identify patients with breast cancer who would be eligible for additional medical management; the Company working with commercial partners in Japan to ensure that BRACAnalysis is available to patients; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

2019 GlobeNewswire, Inc. All Rights Reserved.

SOURCE: Myriad Genetics, Inc.

Read the original:
Myriad Genetics Announces Regulatory Approval Of The BRACAnalysis Diagnostic System In Japan For Breast Cancer Patients - Laboratory Network

Designer baby, anyone? A New Jersey startup company, Genomic Prediction, might be able to help you.

Genomic Prediction claims to be able to use DNA testing to predict disease risk in an embryo. The idea is to study hundreds or thousands of small variations in DNA, known as genetic markers, and use sophisticated computer algorithms to correlate these with diseases such as type 1 and type 2 diabetes, breast cancer and intellectual disability.

If the companys recent research is any guide, it may move on to predicting other traits such as height and even educational attainment.

But the connections between genetic variations and differences in real human beings are far from straightforward. And even if we can make these connections, should we?

In my own field, forensic genetics, we have a similar goal: to produce a molecular photofit or DNA mugshot of the perpetrator of a crime, using DNA left at a crime scene. At first, there was great optimism.

Only six genetic markers were required to predict blue or brown eye colour with reasonable accuracy. However, prediction of intermediate eye colours (green, hazel, light brown) was less accurate. Testing for hair colour soon followed (24 markers) and, most recently, skin colour (41 markers).

Eye, hair and skin colour are all largely controlled by a small number of genes related to the pigment melanin. There are two types of melanin, a dark and a light form, and between them they give rise to the spectrum of eye, hair and skin colours.

Read more: World's first genetically modified human embryo raises ethical concerns

High doses of the light pigment are found only in individuals with European ancestry, particularly northern European. Prediction systems have really only been developed and tested rigorously on Europeans and North Americans.

This is the case with many large genome-wide association studies (GWAS) and data sets, including some of those used by Genomic Prediction. Individuals without European ancestry are poorly represented, and the associations between genetic markers and traits dont always replicate in populations that dont have European ancestry.

Since these first few pigmentation prediction systems, progress has been slow in forensic genetics. This is because most traits even ones that are strongly influenced by genetics are very polygenic, which means they are influenced by many different genes.

For example, height and educational attainment are both highly heritable. But they are under the influence of hundreds, if not thousands, of genetic markers, each with a very small effect on the trait.

Further, the marker variants with the largest influence are generally the rarest ones. For example, the variants with the largest influence on height each account for only one or two centimetres and are present in no more than 0.2% of the population. More common variants each account for height differences of mere millimetres or even less.

Polygenic scores add up all the tiny effects of these multiple marker variants to give an overall prediction. But there are several caveats.

First, they dont take account of genetic synergies (epistasis). The effects of two (or more) different markers may not add up in any simple way.

Second, they completely ignore environmental effects: the nurture part of nature versus nurture. For example, although both are highly heritable, height is affected by nutrition, and educational attainment is influenced by educational expectations and parental education. So, really, what is being predicted is the genetic potential for a particular trait.

Assuming Genomic Prediction can predict these potentials accurately, will they all be found in one embryo?

Lets say you want a tall, brown-eyed, high educational achiever with a low risk of breast cancer. The odds of finding all of these potentials in one embryo is very low, like throwing dozens of dice and having them all come up with sixes.

Even if you are lucky with your roll of the genetic dice, are you sure your designer baby will thank you when they grow up? Your idea of the perfect trait might not be theirs. You are, in effect, choosing their DNA without their consent.

Read more: 3-parent IVF could prevent illness in many children (but it's really more like 2.002-parent IVF)

Are you ready to see a prediction of what your baby might look like as an adult, or a photo-board from which to choose your future offspring? Companies are already offering to produce molecular photofits of unknown donors of crime-scene DNA. Its not a giant leap to designer babies.

At US$1,000 per case and an additional US$400 per screened embryo for expanded pre-implantation genomic testing (EPGT is Genomic Predictions flagship product), designer babies will inevitably be more available to wealthier parents. There are valid concerns that this could lead to genetic advantage and disadvantage along socio-economic lines.

Genetic screening is already common practice, especially for chromosomal disorders. Like many others, my own daughter received a nuchal fold thickness assessment as a standard ultrasound screen for Down syndrome.

Screening for genetic risks is just one more step along this continuum. But how many steps should we take? Once we start selecting for desirable characteristics, its easy to see the moral slope becoming very slippery.

Continued here:
An American company will test your embryos for genetic defects. But designer babies aren't here just yet - The Conversation AU

115 more arazi centres to be set up

LAHORE :The Punjab government will set up 115 arazi centres in different districts of the province by the end of the current year to facilitate the general public at their doorstep.

The arazi centres will provide revenue related facilities to the general public in an efficient and transparent manner.

This was stated by Provincial Minister for Revenue Malik Muhammad Anwar while talking to different delegations at his office on Friday.

The minister said that 153 arazi record centres were already providing different facilities to the people in 36 districts of the province.

He said the Board of Revenue was going to procure 20 state-of-the-art mobile vans so that revenue-related facilities could be provided to the people close to their residence.

The BOR has also taken steps to facilitate the rural population and computer technology has been utilised to facilitate the people.

The PTI led government has given special attention to ensuring complete transparency in revenue matters to save public properties from land grabbers, the minister concluded.

Magistrates: A spokesman for the Provincial Industries and Trade Department has the price control magistrates are conducing raids to check the price of essential commodities across the province.

The spokesman stated the price control magistrates conducted raids on 10,350 shops.

As many as 1,952 complaints relating to price-hike were lodged and 189 cases were registered in which 179 persons were arrested and fines amounting to more than Rs3.5 million were also imposed.

PhDs awarded: Punjab University (PU) has awarded PhD degrees to five scholars.

Ambreen Gul, daughter of Mirza Sultan Ahmed, has been awarded PhD in Molecular Biology after approval of her thesis entitled Overexpression of Aspartic Acid in Cotton Against Insects, Ammara Ahad, d/o Abdul Ahad Khan, in Molecular Biology after approval of her thesis entitled Expression of Flavonoid Pigment Related Genes in Cotton (Gossypium hirsutum), Khadija Aaliya, d/o Asif Hussain, Molecular Biology after approval of her thesis entitled Transformation and Expression Studies of Multiple Frost Tolerant Genes in Solanum Tuberosum L, Mehvish Ajaz, d/o Soofi Ajaz Ahmed, in Microbiology and Molecular Genetics after approval of her thesis entitled Azo Dyes Removal by Bacteria Isolated from Industrial Wastewater and Naveed Ahmad Noor, son of Muhammad Nawaz, in the subject of High Energy Physics after approval of his thesis entitled Under Pressure Study of Fundamental Properties of Perovskite Oxides Using Density Functional Theory (DFT).

Go here to see the original:
115 more arazi centres to be set up - The News International

Fish that adapted to survive in the frigid waters of Antarctica offer a gateway to better understand the genetics of human aging, but the fish are being threatened by climate change, says University of Oregon biologist John Postlethwait.

Thats the message he will deliver Nov. 13 in a Quack Chats pub talk at Eugenes Downtown Athletic Club, 999 Willamette St. The talk will begin at 6 p.m. in the third-floors Ax Billy Grill.

These are remarkably beautiful and complex animals, said Postlethwait, a professor emeritus and member of the UOs Institute of Neuroscience. Climate change is threatening them. We need to study them more before they become extinct or try to change the conditions so that we limit the effects of climate change and maybe reduce the chances of extinction.

Postlethwait traveled five times to Antarctica between 2008 and 2018 with funding from the National Institutes of Health and National Science Foundation. He has studied dragonfish and icefish, primarily the low bone mineralization that evolved in bottom-dwelling icefish to allow them to increase their buoyancy and rise in the water column to feed.

That adaptation of turning off certain genes to become less dense in the absence of swim bladders think lungs in humans began about 30 million years ago as Antarctic waters cooled. Todays seawater temperature there hovers just below the freezing point of fresh water.

The bones in these fish look like old peoples bones, said Postlethwait, who ran a marathon in Antarctica during one of his research trips. As people age, they turn off or turn down the genes that are important for maintaining bone health.

In his talk, Dragons and Icefish: Surviving Frigid Antarctic Seas, hell detail the biology and molecular genetics of these Antarctic fish and how they hold genetic clues that may be useful for understanding anemia, oversized hearts and low bone-mineral density in humans.

The potential human health payoff was boosted earlier this year when an international team that included Postlethwait and six other UO researchers published the complete genome sequence for Antarctic blackfin icefish.

To learn more about upcoming Quack Chats, see the Quack Chats section on Around the O. A general description of Quack Chats and a calendar of additional Quack Chats and associated public events also can be found on the UOs Quack Chats website.

By Jim Barlow, University Communications

Excerpt from:
Pub talk will explore links between icefish and human aging - AroundtheO

A team of UBC researchers used advanced techniques in microscopy and chemical profiling to determine that cannabis flowers with the biggest hairs produce the most CBD, THC, and fragrance-emitting terpenes.

The research was the first to detail the structures and chemical-creating abilities of the three kinds of frostlike pot hairsstalked, sessile, and bulbouscalled glandular trichomes.

Finola, a fast-flowering hemp variety of Cannabis sativa, was used by the team, which included researchers from UBC's Wine Research Centre and the Michael Smith Laboratories.

Teagen Quilichini, the study's co-lead author and a postdoctoral fellow with the botany department, said in an October 28 UBC news release that the study is an important beginning for subsequent research.

Despite its high economic value, our understanding of the biology of the cannabis plant is still in its infancy due to restricted legal access, Quilichinisaid. Trichomes are the biochemical factories of the cannabis plant and this study is the foundation for understanding how they make and store their valuable products.

The paper"Cannabis glandular trichomes alter morphology and metabolite content during flower maturation"appeared in the August 30 edition of the Plant Journal.

Anne Lacey Samuels, a botany professor and principal investigator for the study, said in the release that there could be many downstream benefits of the research.

We found a treasure trove of genes that support the production of cannabinoids and terpenes. With further investigation, this could be used to produce desirable traits like more productive marijuana strains or strains with specific cannabinoid and terpene profiles using molecular genetics and conventional breeding techniques.

The UBC team determined under ultraviolet light that the stalked trichomes glowed blue and had large, distinctive secretory discs of cells that looked like microscopic mushrooms or hamburgers.

We saw that stalked glandular trichomes have expanded 'cellular factories' to make more cannabinoids and fragrant terpenes, co-lead author Sam Livingston said in the release. We also found that they grow from sessile-like precursors and undergo a dramatic shift during development that can be visualized using new microscopy tools."

Livingston, a botany department PhD candidate, noted thatUV lightmight be used todetermine flowers' trichome maturity so growers would know the best times to harvest.

See the original post here:
UBC cannabis researchers find that "frosty" flowers mean potent pot - Straight.com

Graph 1

Vectra Predicts Risk of Radiographic Progression in 1 Year

Myriad Genetics, Inc.

Graph 2

Vectra Predicts Risk of Cardiovascular Events in Patients with RA

Myriad Genetics, Inc.

SALT LAKE CITY, Nov. 09, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in precision medicine, announced that its Myriad Autoimmune business unit will present new data on the Vectra test at the 2019 ACR/ARP Annual Meeting being held Nov. 8-13, 2019 in Atlanta, GA. The key findings are that the Vectra test predicts the risk of radiographic progression (RP) within one year, and the Vectra score, in combination with other clinical measures, predicts the risk of a cardiovascular (CV) event in people with rheumatoid arthritis (RA).

A hallmark feature ofrheumatoid arthritisisinflammation, which increases the risk of joint damage, cardiovascular disease and other comorbidities, said Elena Hitraya, M.D., Ph.D., rheumatologist and chief medical officer at Myriad Autoimmune. The data being presented by our academic collaborators at ACR show that the Vectra test accurately measures inflammation and can help predict patients risk of adverse health outcomes, enabling clinicians to tailor precision treatment plans to achieve better outcomes.

Vectra Posters

Title:Predicting Risk of Radiographic Progression for Patients with Rheumatoid Arthritis.Presenter:Jeff Curtis, M.D., M.S., MPH, University of Alabama at Birmingham.Date:Sunday, Nov. 10, 2019. 9:00-11:00 a.m.Location:Poster 466.

This study evaluated the ability of the Vectra test to predict patients individual percentage risk of RP within one year. The analysis included combined data from 973 patients in four cohorts. The results demonstrate that the adjusted Vectra score was a superior predictor of RP within one year compared to DAS28-CRP, CRP, CDAI and swollen joint count. Additionally, the risk of permanent joint damage increased continuously with the adjusted Vectra score, meaning patients with a low adjusted Vectra score had a one to three percent risk of RP in one year, while patients with a moderate-to-high score had between seven and 47 percent risk (Graph 1). Based on these new data, the company is working to enhance the Vectra test report to provide patients with their individual risk of radiographic progression in one year.

To view Graph 1: Vectra Predicts Risk of Radiographic Progression in 1 Year,please visit the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/514919cd-81ca-4084-81df-682fedc1784b

Too often people with RA are over- or under-treated because it is difficult for clinicians to accurately measure inflammation and determine the long-term prognosis of RA patients. As a result, some people are at increased risk of rapid radiographic progression, said Jeff Curtis, M.D., M.S., MPH, lead investigator, rheumatologist and Professor of medicine in the Division of Clinical Immunology and Rheumatology at the University of Alabama at Birmingham. It is critical that clinicians have reliable information when making treatment decisions. Our study demonstrated that the Vectra score was the strongest predictor of radiographic progression, which may help inform treatment plans and prevent future joint damage.

Title:Derivation and Validation of a Biomarker-Based Cardiovascular Risk Prediction Score in Rheumatoid Arthritis.Presenter:Jeff Curtis, M.D., M.S., MPH; University of Alabama at Birmingham.Date:Tuesday, Nov. 12, 2019. 9:00-11:00 a.m.Location:Poster 2350.

This study evaluated 30,751 Medicare patients with RA to develop and validate the Vectra CVD score, which predicts risk for a first cardiovascular (CV) event by combining data from Vectra and clinical measures. The primary CV outcome was a composite of three types of CV events heart attack, stroke, and CV death occurring within 3 years from testing. When the performance of the Vectra CVD score was compared to four other CV prediction models, the Vectra CVD score was a significant predictor of CV risk and was superior to all four other models. Importantly, when risk scores were converted to 3-year percentage risk for having a CV event, approximately 80 percent of patients were found to have a moderate or high risk of a CV event over 3 years, based on risk categories analogous to those of the American College of Cardiology/American Heart Association 2018 guidelines (Graph 2).

To view Graph 2: Vectra Predicts Risk of Cardiovascular Events in Patients with RA, please visit the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/c902b4ec-a3c8-439f-9557-0a9b05631a1f

People with rheumatoid arthritis have almost double the risk of heart attack, stroke and atherosclerosis. Traditional CV risk factors alone do not fully explain the increased rates of CV events in RA, and inflammation is a missing component that is measured by the Vectra test, said Dr. Curtis. In this study, the Vectra CVD score effectively predicted CV risk in people with RA. We believe the Vectra CVD score may assist clinicians to more quickly identify patients at high risk for CV events and target interventions that can be potentially life-saving.

The company plans to publish these new data in peer reviewed medical journal and make the Vectra CVD score available to clinicians in fiscal year 2020. Please visit Myriad Autoimmune at booth #1419 to learn more about Vectra. Follow Myriad on Twitter via @myriadgenetics and follow meeting news by using the hashtag #ACR19.

About VectraVectra is a multi-biomarker molecular blood test that provides an objective and personalized measure of inflammatory disease activity in patients with rheumatoid arthritis. Vectra provides unsurpassed ability to predict radiographic progression and can help guide medical management decisions with the goal of improving patient outcomes. Vectra testing is performed at a state-of-the-art CLIA (Clinical Laboratory Improvement Amendments) facility. Test results are reported to the physician five to seven days from shipping of the specimen. Physicians can receive test results by fax or the private web portal, VectraView. For more information on Vectra, please visit: http://www.vectrascore.com.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company presenting new data on the Vectra test at the 2019 ACR Annual Meeting; the Vectra test enabling clinicians to tailor precision treatment plans to achieve better outcomes; the Vectra score helping inform treatment plans and prevent future joint damage; the Vectra CVD score assisting clinicians to more quickly identify patients at high risk for CV events and target interventions that can be potentially life-saving; publishing these new data in peer reviewed medical journal; making the Vectra CVD score available to clinicians in fiscal year 2020; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Go here to read the rest:
New Studies Demonstrate the Predictive Value of the Vectra Test in People Diagnosed with Rheumatoid Arthritis - GlobeNewswire